Tiotropium for moderate-to-severe chronic obstructive pulmonary disease: a review of the clinical effectiveness and cost-effectiveness
Tran K, Nkansah E
Record ID 32011001205
English
Authors' recommendations:
Compared with LABAs (formoterol, salmeterol), tiotropium was associated with greater improvement of lung function, but had comparable effects on COPD exacerbations, hospitalizations, dyspnea improvement, health-related quality of life, and all-cause mortality. There was no difference in exacerbation rate and lung function between tiotropium and LABA plus inhaled glucocorticoids (fluticasone). Combination therapy of tiotropium and LABA further improved lung function. The most common adverse event of tiotropium was dry mouth. One meta-analysis showed that long term treatment of tiotropium (1 to 5 years) was associated with a significantly increased risk of cardiovascular death, MI, or stroke. Based on the economic studies identified, tiotropium treatment appears to be cost-effective alternative compared with salmeterol. A cost-effectiveness study should be conducted using clinical outcome measures obtained from recent systematic reviews and meta-analyses, or it should be conducted side by side with a long-term trial that is independent of the support of pharmaceutical companies.
Details
Project Status:
Completed
Year Published:
2009
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Pulmonary Disease, Chronic Obstructive
- Scopolamine Derivatives
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.